drugset / Trial / NCT07490041
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
Phase 0
Recruiting
36 enrolled
The Children's Hospital of Zhejiang University School of Medicine
Rui Therapeutics Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA CAR-NK cell injection in patients with refractory pediatric rheumatic diseases.
Timeline
- Start
- 2026-03-19
- Primary completion
- 2026-12-19
- Completion
- 2027-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KN5601 | Cell therapy | — | — |